文献速递皮肤肿瘤

计算肿瘤面积(CTA)作为皮肤恶性黑色素瘤预后工具的开发和初步验证

Development and Initial Validation of Calculated Tumor Area as a Prognostic Tool in Cutaneous Malignant Melanoma.
PubMed 文献 · JAMA Dermatol · 2019-01-01

本研究回顾性纳入英国莱斯特和诺丁汉两个队列共1239例皮肤黑色素瘤患者,开发并验证二维特征计算肿瘤面积(CTA)的预后价值。结果显示CTA是独立于Breslow厚度的预后因素,在莱斯特队列HR为1.87,诺丁汉验证队列HR为1.55,合并HR为1.70。

要点

  • CTA是独立于Breslow厚度的预后因素,合并队列HR为1.70。
  • CTA在全部100个bootstrap多变量模型中被保留,Breslow厚度仅53个。
  • 按CTA分层生存曲线分离优于按Breslow厚度分层。

核心结论

  • CTA是一种新型显微镜特征,具有独立预后价值,应优先进一步研究。

研究设计与样本

  • 回顾性队列研究,纳入英国莱斯特和诺丁汉NHS医院信托的皮肤黑色素瘤患者,最终研究人群1239例。

主要发现

  • 莱斯特队列918例中,调整Breslow厚度、年龄、性别、溃疡、核分裂率和微卫星后,CTA的HR为1.87(95%CI 1.49-2.34,P<.001)。
  • 诺丁汉验证队列321例中,CTA的HR为1.55(95%CI 1.15-2.09,P=.005)。
  • 合并1239例中,CTA的HR为1.70(95%CI 1.43-2.03,P<.001)。
  • Breslow厚度仅在CTA不在模型时多变量分析中显著。
  • 按CTA分层生存曲线HR范围1.00至41.46,按Breslow厚度分层HR范围1.00至36.95。

关键数值与推荐

  • CTA在13例病例上的组内相关系数为0.99。
  • 含CTA分类的模型与T分类相比,贝叶斯信息准则差异为13.9。
  • 模型Harrell C指数为83.7%,校正校准斜率为0.99。

临床怎么用

  • CTA可作为皮肤黑色素瘤的预后评估工具,但需进一步研究验证后方可用于临床决策。

局限性

  • 本研究为回顾性队列设计,样本来自英国两个中心,外部泛化性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Breslow thickness is a 1-dimensional surrogate prognostic feature for tumor size, yet tissue sections have 2 dimensions. Therefore, a 2-dimensional feature, calculated tumor area (CTA), was devised. OBJECTIVE: To determine CTA precision and prognostic value. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort of patients with cutaneous melanoma presented to the Leicester and Nottingham National Health Service hospital trusts in the United Kingdom. Eligible patients in the Leicester development sample had available primary tumor tissue; a diagnosis from January 1, 2004, through December 31, 2011; invasive disease; and Leicestershire residency. Patients in the Nottingham validation sample had an anonymized spreadsheet with primary melanoma diagnosed from January 1, 2003, through December 31, 2005, or from January 1, 2008, through December 31, 2010. From a starting population of 1463 patients in both data sets, a total of 224 (15.3%) were excluded to yield a study population of 1239. Data were analyzed from April 30, 2018, through January 10, 2019. INTERVENTION: An observational analysis of the prognostic value of CTA in patients with cutaneous melanoma. MAIN OUTCOMES AND MEASURES: Independent association of CTA with melanoma-specific survival and confounding effect of CTA on Breslow thickness in survival analysis. RESULTS: A total of 1239 patients with melanoma were assessed, including 649 (52.4%) women, with a median age of 60 years (interquartile range, 47-71 years). An intraclass correlation coefficient for CTA on 13 cases was 0.99. In 918 patients in the Leicester cohort, CTA was an independent prognostic factor in Cox proportional hazards regression models after adjusting for Breslow thickness, age, sex, ulcer, mitotic rate, and microsatellites (hazard ratio [HR], 1.87; 95% CI, 1.49-2.34; P < .001). Validation in 321 patients in the Nottingham cohort showed an HR of 1.55 (95% CI, 1.15-2.09; P = .005) and in the combined 1239 cases, an HR of 1.70 (95% CI, 1.43-2.03; P < .001). Breslow thickness was significant in multivariable analysis only when CTA was not in the model. The relative importance of CTA was shown by its retention in all 100 bootstrap multivariable models with backward selection, whereas Breslow thickness was retained in only 53. Melanomas stratified by CTA showed wider separation of survival curves than those stratified by Breslow thickness using the American Joint Committee on Cancer Staging Manual, 8th Edition (HRs, 1.00 to 41.46 vs 1.00 to 36.95, respectively), and the model with CTA categories had a Bayesian information criterion difference of 13.9 compared with T category, indicating substantially better fit. This model had a Harrell C index of 83.7%, and bootstrap analysis showed little evidence of model optimism, with a corrected calibration slope of 0.99. CONCLUSIONS AND RELEVANCE: This study provides a novel microscopic feature, CTA, with evidence of its independent prognostic value. This evidence suggests that CTA should be a priority for further study.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Saldanha G, Yarrow J, Elsheikh S, et al. Development and Initial Validation of Calculated Tumor Area as a Prognostic Tool in Cutaneous Malignant Melanoma. JAMA Dermatol. 2019. PMID: 31241720. doi:10.1001/jamadermatol.2019.0621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。